CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Animals
Antibodies, Bispecific
/ pharmacology
Apoptosis
Cell Proliferation
Colonic Neoplasms
/ immunology
Female
Humans
Immunotherapy
Killer Cells, Natural
/ immunology
Lymphocyte Activation
/ immunology
Mice
Mice, Inbred BALB C
Receptors, OX40
/ immunology
T-Lymphocytes, Regulatory
/ immunology
Tumor Cells, Cultured
Tumor Necrosis Factor Receptor Superfamily, Member 9
/ immunology
Xenograft Model Antitumor Assays
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
15
10
2019
revised:
31
01
2020
accepted:
31
03
2020
pubmed:
11
4
2020
medline:
5
1
2021
entrez:
11
4
2020
Statut:
ppublish
Résumé
Following the success of immune checkpoint blockade therapy against cancer, agonistic antibodies targeting T-cell costimulatory pathways are in clinical trials. The TNF superfamily of receptors (TNFRSF) members CD137 and OX40 are costimulatory receptors that stimulate T-cell proliferation and activation upon interaction with their cognate ligands. Activating CD137 and OX40 with agonistic mAbs stimulates the immune system due to their broad expression on CD4
Identifiants
pubmed: 32273279
pii: 2326-6066.CIR-19-0798
doi: 10.1158/2326-6066.CIR-19-0798
doi:
Substances chimiques
Antibodies, Bispecific
0
Receptors, OX40
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
781-793Informations de copyright
©2020 American Association for Cancer Research.